AR050425A1 - Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas - Google Patents
Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticasInfo
- Publication number
- AR050425A1 AR050425A1 ARP050102848A ARP050102848A AR050425A1 AR 050425 A1 AR050425 A1 AR 050425A1 AR P050102848 A ARP050102848 A AR P050102848A AR P050102848 A ARP050102848 A AR P050102848A AR 050425 A1 AR050425 A1 AR 050425A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- optionally
- group
- aryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Abstract
Se presentan compuestos que se unen a VLA-4. algunos de estos compuestos también inhiben la adhesion leucocitaria y, particularmente, la adhesion leucocitaria mediada por VLA-4. estos compuestos son usados en el tratamiento de enfermedades inflamatorios en un paciente mamífero, por ejemplo, humanos, tales como asma, enfermedad de Alzheimer, ateroesclerosis, demencia por SIDA, diabetes, enfermedad intestinal inflamatoria, artritis reumatoide, transplantes de tejidos, metástasis tumorales e isquemia miocárdica. Los compuestos también pueden administrarse para el tratamiento de enfermedades cerebrales inflamatorias, tal como la esclerosis multiple. Reivindicacion 1: Un conjugado de la formula (1), B es una fraccion polimérica biocompatible opcionalmente unido en forma covalente a una molécula central de cadena ramificada; q es de aprox. 2 hasta aprox. 100; A en cada ocurrencia es independientemente un compuesto de formula (2), o una sal farmacéuticamente aceptable de los mismos componentes, donde J se selecciona de: a) un grupo de formula (3), donde R31 es un enlace covalente con la fraccion polimérica que opcionalmente comprende un ligador, o R31 es -H, R31', -NH2, -NHR31' o -N(R31')2, -'NC3- 6cíclico, -OR31', -SR31' donde cada R31' es independientemente un C1-6 alquílico lineal o ramificado opcionalmente sustituido o C1-6 alquílico opcionalmente sustituido, C3-6 cicloalquílico opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido; y R32 es un enlace covalente con la fraccion polimérica que opcionalmente comprende un ligador, o R32 es -H, -NO2, haloalquilo o el grupo -N(MR41)R42 donde M es un enlace covalente, -C(O)- o -SO2-, R41 es R41', N(R41')2, o -OR41'; donde cada R41' es independientemente hidrogeno, un C1-6 alquilo lineal o ramificado opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heterocíclico opcionalmente sustituido o un heteroarilo opcionalmente sustituido, donde las sustituciones opcionales son haluro, C1-6 alquilo, o -OC1-6alquilo; y R42 es hidrogeno o R41'; y b) un grupo de formula (4), donde R se selecciona de un grupo que consiste en un enlace covalente con la fraccion polimérica, amino, hidroxilo, amino sustituido, alquilo, alquiloxi, ariloxi, heteroariloxi, heterocicliloxi, tiol, ariltio, heteroariltio, heterocicliltio y alquilo sustituido, donde cada amino, amino, sustituido, alquilo y alquilo sustituido esta opcionalmente unido en forma covalente a la fraccion polimérica donde, en cada caso, la fraccion polimérica comprende opcionalmente un ligador que se une covalentemente a la fraccion polimérica; Ar1 se selecciona de un grupo formado por aril, aril sustituido, heteroarilo y heteroarilo sustituido donde cada arilo, arilo sustituido, heteroarilo y heteroarilo sustituido está opcionalmente unido en forma covalente a la fraccion polimérica donde la fraccion polimérica comprende opcionalmente un ligador que une la fraccion polimérica a Ar1; Ar2 se selecciona de un grupo formado por arilo, arilo sustituido, heteroarilo y heteroarilo sustituido donde cada arilo, arilo sustituido, heteroarilo y heteroarilo sustituido está opcionalmente unido en forma covalente a la fraccion polimérica donde la fraccion polimérica comprende opcionalmente un ligador que une la fraccion polimérica a Ar2; X se selecciona del grupo formado por -NR1-, -O-, S-S, -SO-, -SO2 y -CH2- opcionalmente sustituido donde R1 se selecciona del grupo formado por hidrogeno y alquilo; T se selecciona de: a) un grupo de formula (5), donde Y se selecciona de un grupo formado por -O- y -NR1- donde R1 se selecciona del grupo formado por hidrogeno y alquilo; W se selecciona del grupo formado por un enlace covalente unido a una fraccion polimérica que opcionalmente comprende un ligador y -NR2R3 donde R2 y R3 son seleccionados independientemente en el grupo formado por hidrogeno, alquilo, alquilo sustituido y donde R2 y R3, junto con el átomo de nitrogeno allí enlazado, forman un anillo heterocíclico o un anillo heterocíclico sustituido en donde cada alquilo, alquilo sustituido, heterocíclico y heterocíclico sustituido está opcionalmente unido en forma covalente a una fraccion polimérica que además comprende opcionalmente un ligador; m es un entero igual a 0, 1 o 2; n es un entero igual a 0, 1 o 2; y b) un grupo de formula (6), donde G es un arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido con anillo de 5 o 6 miembros conteniendo 0 a 3 nitrogenos, donde dicho arilo o heteroarilo opcionalmente comprende también un enlace covalente con la fraccion polimérica que opcionalmente comprende un ligador; R6 es un enlace covalente con una fraccion polimérica que opcionalmente comprende un ligador, o R6 es -H, alquilo, alquilo sustituido o -CH2C(O)R17, donde R17 es -OH, OR18, o -NHR18, donde R18 es alquilo, alquilo sustituido, arilo o arilo sustituido; R55 se selecciona del grupo compuesto por amino, amino sustituido, alcoxi, alcoxi sustituido, cicloalcoxi, cicloalcoxi sustituido, ariloxi y ariloxi sustituido, y -OH; con tal de que: A es al menos uno de R, Ar1, Ar2, y T contenga un enlace covalente con la fraccion polimérica; B es cuando R esté unido covalentemente a la fraccion polimérica, n sea uno y X no sea -O-, -S-, -SO-, o -SO2-; C es cuando X sea -O- o -NR1-, entonces m sea dos; y D es el conjugado de la formula (1) tenga un peso molecular menor que 100,000.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58697504P | 2004-07-08 | 2004-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050425A1 true AR050425A1 (es) | 2006-10-25 |
Family
ID=35501261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102848A AR050425A1 (es) | 2004-07-08 | 2005-07-08 | Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas |
Country Status (20)
Country | Link |
---|---|
US (4) | US7794700B2 (es) |
EP (4) | EP2298356A3 (es) |
JP (1) | JP2008505927A (es) |
KR (1) | KR101273614B1 (es) |
CN (1) | CN101035563B (es) |
AR (1) | AR050425A1 (es) |
AU (1) | AU2005265316B2 (es) |
BR (1) | BRPI0513143A (es) |
CA (1) | CA2573245C (es) |
EA (1) | EA012433B1 (es) |
EC (1) | ECSP077231A (es) |
HK (1) | HK1111674A1 (es) |
IL (1) | IL180558A0 (es) |
MA (1) | MA28786B1 (es) |
MX (1) | MX2007000228A (es) |
NO (1) | NO20070216L (es) |
NZ (1) | NZ588839A (es) |
TW (1) | TWI418346B (es) |
WO (1) | WO2006010054A2 (es) |
ZA (1) | ZA200700238B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143929A0 (en) * | 1999-01-22 | 2002-04-21 | Elan Pharm Inc | Acyl derivatives which treat vla-4 related disorders |
US7595318B2 (en) * | 2004-01-23 | 2009-09-29 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
CN101035563B (zh) * | 2004-07-08 | 2012-03-28 | 艾伦药物公司 | 包括聚合物部分的多价vla-4拮抗剂 |
CN101300255A (zh) * | 2005-05-20 | 2008-11-05 | 艾伦药物公司 | 咪唑啉酮苯丙氨酸衍生物vla-4拮抗剂 |
EP1901778A2 (en) * | 2005-07-08 | 2008-03-26 | Elan Pharmaceuticals Inc. | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
CA2851103A1 (en) | 2005-09-29 | 2007-04-12 | Elan Pharmaceuticals, Inc. | Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO2007041270A1 (en) * | 2005-09-29 | 2007-04-12 | Elan Pharmaceuticals, Inc. | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO2007060409A1 (en) * | 2005-11-23 | 2007-05-31 | Astrazeneca Ab | L-alanine derivatives |
CA2643838A1 (en) * | 2006-02-27 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO2007100763A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
JP2009528359A (ja) * | 2006-02-28 | 2009-08-06 | エラン ファーマシューティカルズ,インコーポレイテッド | ナタリズマブを用いて炎症性疾患および自己免疫性疾患を治療する方法 |
KR20080104343A (ko) * | 2006-03-03 | 2008-12-02 | 엘란 파마슈티칼스, 인크. | 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법 |
JP2009538338A (ja) * | 2006-05-22 | 2009-11-05 | イーラン ファーマスーティカルズ、インコーポレイテッド | 治療用、農業用及び食品添加用化合物のポリマー複合体の調製 |
JP2009539815A (ja) * | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のa5b1アンタゴニストとしてのN−(ベンゾイル)−O−[2−(ピリジン−2−イルアミノ)エチル]−L−チロシン誘導体と関連化合物 |
WO2008093065A1 (en) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS |
US20100150915A1 (en) | 2007-02-20 | 2010-06-17 | Stewart Edward J | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
WO2008153967A1 (en) * | 2007-06-08 | 2008-12-18 | Contec Therapeutics, Inc. | Bk1 antagonist conjugates |
JP2011506322A (ja) * | 2007-12-07 | 2011-03-03 | エラン ファーマシューティカルズ,インコーポレイテッド | 液性腫瘍を治療するための方法および組成物 |
EP2085407A1 (en) | 2008-02-04 | 2009-08-05 | Sahltech I Göteborg AB | Treatment of idiopathic thrombocytopenic purpura |
CN102459179A (zh) * | 2009-04-27 | 2012-05-16 | 艾伦药物公司 | α-4整联蛋白的吡啶酮拮抗剂 |
EP2467159A1 (en) * | 2009-08-20 | 2012-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
HUE060312T2 (hu) | 2010-01-11 | 2023-02-28 | Biogen Ma Inc | A JC vírus antitestek vizsgálata |
EP2525831B1 (en) * | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
CA2797974A1 (en) | 2010-04-30 | 2011-11-03 | Elan Pharmaceuticals, Inc. | Selective integrin inhibitors |
EP2739690B1 (en) | 2011-08-03 | 2016-08-10 | Henkel IP & Holding GmbH | Electrically conductive structural adhesive |
CA2902624C (en) | 2013-02-28 | 2021-05-18 | Takeda Pharmaceutical Company Limited | Method for producing sulfonyl chloride compound |
EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | METHODS OF EVALUATION RISK OF DEVELOPMENT OF PML |
WO2015003156A1 (en) * | 2013-07-05 | 2015-01-08 | Biogen Idec Ma Inc. | Compositions and methods for treatment of stroke |
US20150250883A1 (en) * | 2014-02-12 | 2015-09-10 | 7 Hills Pharma, Llc | Compositions and methods to improve the homing and grafting of hematopoetic stem cells |
US20200255530A1 (en) * | 2015-07-23 | 2020-08-13 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
CR20210213A (es) | 2018-10-30 | 2021-06-24 | Gilead Sciences Inc | Derivados de quinolina como inhibidores de la integrina alfa4beta7 |
AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリンの阻害のための化合物 |
AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5177059A (en) | 1989-11-15 | 1993-01-05 | Sandoz Ltd. | Polymyxin B conjugates |
DE4107857A1 (de) | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
EP0576589A4 (en) | 1991-03-18 | 1994-07-27 | Enzon Inc | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
EP1001764A4 (en) * | 1997-05-29 | 2005-08-24 | Merck & Co Inc | Heterocyclic amides as cell adhesion inhibitors |
AU726585B2 (en) | 1997-05-29 | 2000-11-09 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
AR016133A1 (es) | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
US6489300B1 (en) * | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6939855B2 (en) * | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
CA2323048C (en) | 1998-03-12 | 2006-10-10 | Shearwater Polymers, Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
GB9821061D0 (en) * | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
IL143929A0 (en) * | 1999-01-22 | 2002-04-21 | Elan Pharm Inc | Acyl derivatives which treat vla-4 related disorders |
AU2623900A (en) | 1999-01-22 | 2000-08-07 | American Home Products Corporation | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
JP2003506491A (ja) * | 1999-08-13 | 2003-02-18 | バイオジェン インコーポレイテッド | 細胞接着インヒビター |
AU2001233069A1 (en) * | 2000-01-28 | 2001-08-07 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
WO2002008202A2 (en) | 2000-07-21 | 2002-01-31 | Elan Pharmaceuticals, Inc. | Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by vla-4 |
US20040043030A1 (en) | 2001-07-31 | 2004-03-04 | Immunomedics, Inc. | Polymeric delivery systems |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
ES2197003B1 (es) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | Nuevos compuestos antagonistas de integrinas alfa. |
TWI281470B (en) * | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
TW200307671A (en) * | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
US20050069541A1 (en) | 2003-01-24 | 2005-03-31 | Karlik Stephen J. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
US7605166B2 (en) | 2003-06-25 | 2009-10-20 | Elan Pharmaceuticals Inc. | Methods and compositions for treating rheumatoid arthritis |
US7595318B2 (en) | 2004-01-23 | 2009-09-29 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
JP2007531735A (ja) | 2004-04-01 | 2007-11-08 | エラン ファーマシューティカルズ,インコーポレイテッド | ステロイド節約剤および該節約剤を使用する方法 |
US7205310B2 (en) * | 2004-04-30 | 2007-04-17 | Elan Pharmaceuticals, Inc. | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4 |
CN101035563B (zh) | 2004-07-08 | 2012-03-28 | 艾伦药物公司 | 包括聚合物部分的多价vla-4拮抗剂 |
CN101300255A (zh) * | 2005-05-20 | 2008-11-05 | 艾伦药物公司 | 咪唑啉酮苯丙氨酸衍生物vla-4拮抗剂 |
EP1901778A2 (en) * | 2005-07-08 | 2008-03-26 | Elan Pharmaceuticals Inc. | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
JP2011506322A (ja) | 2007-12-07 | 2011-03-03 | エラン ファーマシューティカルズ,インコーポレイテッド | 液性腫瘍を治療するための方法および組成物 |
-
2005
- 2005-07-08 CN CN2005800298537A patent/CN101035563B/zh not_active Expired - Fee Related
- 2005-07-08 TW TW094123303A patent/TWI418346B/zh not_active IP Right Cessation
- 2005-07-08 MX MX2007000228A patent/MX2007000228A/es active IP Right Grant
- 2005-07-08 US US11/177,748 patent/US7794700B2/en not_active Expired - Fee Related
- 2005-07-08 EP EP10179711A patent/EP2298356A3/en not_active Withdrawn
- 2005-07-08 EA EA200700212A patent/EA012433B1/ru not_active IP Right Cessation
- 2005-07-08 EP EP10180274A patent/EP2258400A3/en not_active Withdrawn
- 2005-07-08 BR BRPI0513143-0A patent/BRPI0513143A/pt not_active IP Right Cessation
- 2005-07-08 JP JP2007520561A patent/JP2008505927A/ja active Pending
- 2005-07-08 AU AU2005265316A patent/AU2005265316B2/en not_active Ceased
- 2005-07-08 EP EP10179709A patent/EP2258399A3/en not_active Withdrawn
- 2005-07-08 WO PCT/US2005/024369 patent/WO2006010054A2/en active Application Filing
- 2005-07-08 AR ARP050102848A patent/AR050425A1/es not_active Application Discontinuation
- 2005-07-08 KR KR1020077003108A patent/KR101273614B1/ko not_active IP Right Cessation
- 2005-07-08 EP EP05770402A patent/EP1765412A2/en not_active Withdrawn
- 2005-07-08 NZ NZ588839A patent/NZ588839A/xx not_active IP Right Cessation
- 2005-07-08 CA CA2573245A patent/CA2573245C/en not_active Expired - Fee Related
-
2007
- 2007-01-04 IL IL180558A patent/IL180558A0/en unknown
- 2007-01-09 ZA ZA200700238A patent/ZA200700238B/en unknown
- 2007-01-12 NO NO20070216A patent/NO20070216L/no not_active Application Discontinuation
- 2007-02-05 MA MA29658A patent/MA28786B1/fr unknown
- 2007-02-08 EC EC2007007231A patent/ECSP077231A/es unknown
-
2008
- 2008-02-29 HK HK08102319.2A patent/HK1111674A1/xx not_active IP Right Cessation
-
2010
- 2010-09-08 US US12/877,496 patent/US8263063B2/en not_active Expired - Fee Related
-
2012
- 2012-09-07 US US13/606,783 patent/US20120329807A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/831,625 patent/US20130338164A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050425A1 (es) | Antagonistas multivalentes de vla-4 que comprende fracciones polimericas. composiciones farmaceuticas | |
CY1118102T1 (el) | Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων | |
AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
AR104417A2 (es) | Compuestos de tiadiazolidina, procedimiento para su preparación, composición farmacéutica que lo compone y usos de dichos compuestos | |
RU2013152132A (ru) | Борсодержащие малые молекулы в качестве противовоспалительных средств | |
AR023823A1 (es) | Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos. | |
CY1112362T1 (el) | Πολυμερη βασιζομενα σε κυκλοδεξτρινη για χορηγηση των θεραπευτικων μεσων που ειναι ομοιοπολικως δεσμευμενα σε αυτα | |
BR112012018865A2 (pt) | naftiridinas substituídas e seu uso como inibidores de quinase syk | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
HK1084024A1 (en) | Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer | |
AR049333A1 (es) | Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas. | |
JP2009530424A5 (es) | ||
AR046964A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion. | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
EA200970311A1 (ru) | ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-α]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
EA201171328A1 (ru) | Производное замещенного изохинолина | |
AR078121A1 (es) | Compuestos de sales de amonio cuaternario y composiciones farmaceuticas | |
AR067869A1 (es) | Derivados de piridina y pirimidina | |
JP2017531041A5 (es) | ||
MX2015016417A (es) | Conjugados de anticuerpo farmaco. | |
AR065348A1 (es) | Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer | |
RU2009114731A (ru) | Производное пиразолопиримидина | |
RU2012151201A (ru) | Пиперазинотриазины | |
EA200970002A1 (ru) | Двойственные молекулы, содержащие пероксидное производное, их синтез и их терапевтические применения | |
RU2019111768A (ru) | Противораковые агенты и их получение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |